Autologous Transplantation in Transformed Lymphomas: Single Center Experience

Abstract

4-year PFS was 69.2% (95% CI 60.4%-78%) while 4-year OS was 76.4% (95% CI 66.2%-83.6%). Patients presenting MACE after ASCT had a 4-year OS of 64% vs. 76.9% without MACE, however this difference did not reach statistical significance (p¼0.19). Conclusions: Life threating cardiac events are rare in lymphoma patients undergoing ASCT. Only EF<50% before ASCT was statistically significant, traditional RF appear to be associated. Cumulative anthracycline dose and prior thoracic radiation did not increase risk. MACE were similar between BEAM and BEP regimens. Optimized medical therapy and strict fluid balance during ASCT is critical, future studies will be necessary to identify additional RF and potential interventions to prevent MACE.